



B.L.T.

# THE TOXICOLOGICAL SOCIETY OF BELGIUM AND LUXEMBOURG

A.S.B.L. – V.Z.W.

President:  
Prof. A. VERSTRAETE

General secretary:  
Dr. K. MAUDENS

## Final Program

**BLT scientific session and general assembly – March 8<sup>th</sup>, 2018 – UCL Saint-Luc, salle Verrière**

- 18.30 – 18.35:** welcome by our president
- 18.35 – 19.35:** **Guidelines for Therapeutic Drug Monitoring in Psychiatry.**  
Prof. C. Hiemke (University of Mainz, Germany)
- 19.35 – 20.05:** **Royal Decree of 06.09.2017 regulating narcotics and psychotropic substances:  
practical implementation for toxicological laboratories.**  
G. Declercq (FAGG-AFMPS)
- 20.05 – 20.45:** **Free communications**
- **Activity-based detection and bioanalytical confirmation of a fatal carfentanil intoxication.**  
Lars Ambach, Annelies Cannaert, Peter Blanckaert and Christophe Stove
  - **Ionic liquids as promising extraction solvents in toxicology.**  
Marieke De Boeck, Sophie Missotten, Lisa Dubrulle, Wim Dehaen, Jan Tytgat and Eva Cuypers
- 20.45 – ... :** **BLT general assembly followed by reception.**

## Activity-based detection and bioanalytical confirmation of a fatal carfentanil intoxication

Lars Ambach<sup>1</sup>, Annelies Cannnaert<sup>1,2</sup>, Peter Blanckaert<sup>3</sup>, Christophe Stove<sup>\*,1</sup>

<sup>1</sup>Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium

<sup>2</sup>Laboratory of Toxicology, National Institute of Criminalistics and Criminology, Vilvoordsesteenweg 100, 1120 Brussels, Belgium.

<sup>3</sup>Belgian Early Warning System on Drugs, Drugs Program, Scientific Institute of Public Health, Juliette Wytsmanstraat 14, 1050 Brussels, Belgium.

\*Corresponding author:

Christophe Stove, Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium, Phone: +32 9 264 81 35, Fax: +32 9 264 81 83, E-mail: Christophe.Stove@ugent.be

**Keywords:** synthetic opioids; untargeted screening; activity-based; bioassay; carfentanil; LC-MS/MS

---

### Abstract

Carfentanil, one of the most potent opioids known, has recently been reported as a contaminant in street heroin in the USA and Europe, and is associated with an increased number of life-threatening emergency department admissions and deaths. Here, we report on the application of a novel *in vitro* opioid activity reporter assay and a sensitive bioanalytical assay in the context of a fatal carfentanil intoxication, revealing some of the highest carfentanil concentrations reported until now.

A 21-year-old male was found dead at home with a note stating that he had taken carfentanil with suicidal intentions. A foil bag and plastic bag labelled "C.50" were found at the scene. These bags were similar to a sample obtained by the Belgian Early Warning System on Drugs from a German darknet shop and to those found in the context of a fatality in Norway.

Blood, urine and vitreous, obtained during autopsy, were screened with a newly developed *in vitro* opioid activity reporter assay able to detect compounds based on their  $\mu$ -opioid receptor activity rather than their chemical structure. All extracts showed strong opioid activity. Results were confirmed by a bioanalytical assay, which revealed extremely high concentrations for carfentanil and norcarfentanil. It should be noted that carfentanil concentrations are typically in pg/mL, but here they were mid to high ng/mL range for all three matrices. The blood and vitreous contained norcarfentanil in the high pg/mL range. No norcarfentanil was detected in urine.

This is the first report where a novel activity-based opioid screening assay was successfully deployed in a forensic case. Confirmation and quantification using a validated bioanalytical procedure revealed some of the, to our knowledge, highest carfentanil concentrations ever reported in humans.

## IONIC LIQUIDS AS PROMISING EXTRACTION SOLVENTS IN TOXICOLOGY

Marieke De Boeck<sup>a</sup>, Sophie Missotten<sup>a</sup>, Lisa Dubrulle<sup>a</sup>, Wim Dehaen<sup>b</sup>, Jan Tytgat<sup>a</sup>, Eva Cuypers<sup>a</sup>

<sup>a</sup> Toxicology and Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Campus Gasthuisberg, O&N II, P.O. Box 922, Herestraat 49, 3000 Leuven, Belgium.

<sup>b</sup> Molecular Design and Synthesis, Department of Chemistry, KU Leuven, Campus Arenberg, P.O. Box 2404, Celestijnenlaan 200F, 3001 Leuven, Belgium.

### INTRODUCTION

Thorough clean-up of complex biological samples remains a crucial step in analytical processes. To date, solid-phase extraction is frequently applied in sample preparation, however, its main disadvantages are labor-intensive and time-consuming protocols. In this respect, dispersive liquid-liquid micro-extractions (DLLMEs) seem to offer less complex and efficient extraction protocols. Furthermore, ionic liquids (ILs) – liquid salts – are emerging as new promising extraction solvents, thanks to their non-flammable nature, negligible vapor pressures and easily adaptable physiochemical properties.

### OBJECTIVES

In this study, the applicability of ILs as DLLME extraction solvents in toxicology was investigated. Moreover, two multi-analyte IL-DLLME-LC-MS/MS methods were optimized and validated for a large number of benzodiazepines (BZDs), BZD-like hypnotics and antidepressants (ADs).

### METHODS

One mL whole blood was transferred into a conical bottom glass tube. Subsequently, one mL aqueous buffer and 60  $\mu$ L IL (1-butyl-3-methylimidazolium hexafluorophosphate) was added. The glass tube was mixed for 5 min at 50 rpm, using a rotary mixer. Phase separation was obtained by centrifugation for 6 min at 3500 rpm. 10  $\mu$ L of the lower IL layer was collected and diluted 1:10 in methanol. The final extract was analyzed using LC-ESI-MS/MS analysis in scheduled multiple reaction monitoring mode.

### RESULTS

Two targeted multi-analyte procedures were successfully validated for the quantification of 19 BZDs (including 2 BZD-like hypnotics) and 18 ADs. Optimized IL-DLLME protocols for both drug classes were similar and took less than 30 minutes. Both analytical method showed good selectivity. Matrix-matched calibration curves were constructed, based on 7 concentration levels ( $n = 6$ ), covering therapeutic ranges and low toxic plasma concentrations. Deuterated standards were introduced to ensure accurate quantification; 16 deuterated BZD and 3 deuterated AD analogues. Accuracy and precision results met the proposed acceptance criteria (bias, repeatability and intermediate precision  $< 15\%$  or  $< 20\%$  near LOQ) for the majority of BZDs, except for brotizolam, chlordiazepoxide, clobazepam, flunitrazepam, lorazepam and nitrazepam, which could only be determined in a semi-quantitative way. Fluvoxamine was excluded from the AD quantitative method. Deviations were partly explained by incomplete dissolution of tablet extracted standards. Recoveries were within 25% - 127% (BZDs) and 53% - 133% (ADs). Matrix effects indicated ion suppression, which was attributed to the presence of IL.

### CONCLUSION

Overall, the applicability of ILs as promising solvents for the extraction of BZDs and ADs in whole blood was proven. Moreover, fast and easy IL-DLLME-LC-MS/MS methods were developed for the quantification of 19 BZDs (including 2 BZD-like hypnotics) and 18 ADs in whole blood.